.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, patients with metastatic stomach cysts who acquired biomarker-matched treatments based on distributing tumor DNA profiling revealed a higher clinical advantage than those receiving unmatched therapy.